Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 9/20 | 0.41 |
| ▸ | F10 | P00742 | 5/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stevioside SCHEMBL18136369 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL15521913 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL15263551 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL24450708 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL22922182 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL23228765 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL21977148 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL21266958 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL20878260 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL18085811 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3528641-B1 | GLUCOSE BEVERAGE COMPRISING EXOGENOUS FLAVOR SOURCE AND COLOR | BRESLIN PAUL (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11432573-B2 | Food and beverage sweeteners | CAVALERI HEALTH, INC. (CA) | 2022-09-06 | — | — | US | disclosed |
| US-11219229-B2 | Sweetened consumer goods comprising exogenous flavor sources and color | BRESLIN PAUL (US) | 2022-01-11 | — | — | US | disclosed |
| US-20200229475-A1 | FOOD AND BEVERAGE SWEETENERS | CAVALERI FRANCO (CA) | 2020-07-23 | — | — | US | disclosed |
| US-20200154748-A1 | FOOD AND BEVERAGE SWEETENERS | CAVALERI HEALTH, INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| US-20200077681-A1 | SWEETENED CONSUMER GOODS COMPRISING EXOGENOUS FLAVOR SOURCES AND COLOR | BRESLIN PAUL (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190289882-A1 | GLUCOSE BEVERAGE COMPRISING EXOGENOUS FLAVOR SOURCE AND COLOR | BRESLIN PAUL (US) | 2019-09-26 | — | — | US | disclosed |
| US-20180249745-A1 | STEVIA-CONTAINING FOOD AND BEVERAGE COMPOSITIONS | OHLY GMBH (DE) | 2018-09-06 | — | — | US | disclosed |
| EP-3017708-B1 | Sweetening composition | RED BULL GMBH (AT) | 2018-05-02 | — | — | EP | disclosed |
| EP-3138411-A1 | STEVIA-CONTAINING FOOD AND BEVERAGE COMPOSITIONS | Ohly GmbH (DE) | 2017-03-08 | — | — | EP | disclosed |
| EP-3017708-A1 | Sweetening composition | Red Bull GmbH (AT) | 2016-05-11 | — | — | EP | disclosed |
| US-20160113316-A1 | SWEETENING COMPOSITION | RED BULL GMBH (AT) | 2016-04-28 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| US-7405238-B2 | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach | DEPOMED INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1790334-A2 | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach | Depomed, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20030044466-A1 | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach | DEPOMED, INC. (US) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | SELP 987/4885ATM 4525/4885PTPN1 4441/4885 |
| US-20030044466-A1 | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach | FABP6, SI, HASPIN | SELP 3284/4885ATM 4167/4885PTPN1 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.